194 related articles for article (PubMed ID: 37062329)
1. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.
Prajapati DR; Molczyk C; Purohit A; Saxena S; Sturgeon R; Dave BJ; Kumar S; Batra SK; Singh RK
Cancer Lett; 2023 Jun; 563():216185. PubMed ID: 37062329
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
[TBL] [Abstract][Full Text] [Related]
3. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
4. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
5. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
6. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
7. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.
Varney ML; Singh S; Li A; Mayer-Ezell R; Bond R; Singh RK
Cancer Lett; 2011 Jan; 300(2):180-8. PubMed ID: 21035946
[TBL] [Abstract][Full Text] [Related]
8. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.
Singh S; Sadanandam A; Varney ML; Nannuru KC; Singh RK
Int J Cancer; 2010 Jan; 126(2):328-36. PubMed ID: 19585580
[TBL] [Abstract][Full Text] [Related]
10. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
11. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions.
Raghuwanshi SK; Su Y; Singh V; Haynes K; Richmond A; Richardson RM
J Immunol; 2012 Sep; 189(6):2824-32. PubMed ID: 22869904
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
13. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro.
Li Z; Wang Y; Dong S; Ge C; Xiao Y; Li R; Ma X; Xue Y; Zhang Q; Lv J; Tan Q; Zhu Z; Song X; Tan J
Cytokine; 2014 Sep; 69(1):6-13. PubMed ID: 25022956
[TBL] [Abstract][Full Text] [Related]
14. Decreased CXCR1 and CXCR2 expression on neutrophils in anti-neutrophil cytoplasmic autoantibody-associated vasculitides potentially increases neutrophil adhesion and impairs migration.
Hu N; Westra J; Rutgers A; Doornbos-Van der Meer B; Huitema MG; Stegeman CA; Abdulahad WH; Satchell SC; Mathieson PW; Heeringa P; Kallenberg CG
Arthritis Res Ther; 2011; 13(6):R201. PubMed ID: 22152684
[TBL] [Abstract][Full Text] [Related]
15. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
17. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
18. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.
Singh S; Wu S; Varney M; Singh AP; Singh RK
Microvasc Res; 2011 Nov; 82(3):318-25. PubMed ID: 21749879
[TBL] [Abstract][Full Text] [Related]
19. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
20. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.
Varney ML; Li A; Dave BJ; Bucana CD; Johansson SL; Singh RK
Clin Exp Metastasis; 2003; 20(8):723-31. PubMed ID: 14713106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
